Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, Olaf Stüve et al.|The Lancet Neurology|2013Cited by 233
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Douglas L. Arnold et al.|The Lancet Neurology|2021Cited by 192
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple SclerosisLudwig Kappos, Krzysztof Selmaj, David K.B. Li et al.|JAMA Neurology|2016Cited by 103